KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

In this Phase II study (n=74), the objective response rate was 67% (95% CI 53-78%) in the primary analysis, with 57% in remission at a median follow-up of 12.3 months (range 7.0-32.3 months). Common grade >=3 adverse events included cytopenias (94%) and infections (32%).


New England Journal of Medicine